Soleil Boughton Sells 2,339 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.41, for a total transaction of $47,738.99. Following the completion of the sale, the insider now owns 172,274 shares in the company, valued at $3,516,112.34. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, September 17th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50.
• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25.
• On Tuesday, August 6th, Soleil Boughton sold 2,334 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.30, for a total value of $40,378.20.
• On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.29, for a total value of $47,377.15.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $21.56 on Friday. The company has a market cap of $4.63 billion, a PE ratio of -2,156.00 and a beta of 1.06. The firm’s 50 day moving average price is $16.82 and its 200-day moving average price is $17.53. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same period last year, the business posted ($0.03) EPS. The business’s revenue was up 51.8% compared to the same quarter last year. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC grew its stake in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the last quarter. Quest Partners LLC grew its stake in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the last quarter. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health during the second quarter valued at about $111,000. CWM LLC raised its position in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Finally, Amalgamated Bank grew its position in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Bank of America increased their price objective on shares of Hims & Hers Health from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Piper Sandler reiterated a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a report on Tuesday, August 6th. Finally, Jefferies Financial Group boosted their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.07.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.